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Diastolic heart failure with preserved left ven-
tricular (LV) function has been intensively investi-
gated and clinically analysed in recent years. It is
now regarded as the cause of 50–55% of all heart
failure hospital admissions. When compared with
systolic heart failure it prevails in women and the
elderly and coincides with hypertension, atrial fi-
brillation and chronic obturatory lung disease. How-
ever, bearing in mind that diastolic heart failure is
diagnosed in 90% of patients suffering from ischae-
mic heart disease (IHD), we may state that ischae-
mia should be identified as a main cause of impaired
LV diastolic function. Studies and clinical observa-
tions have documented the association between the
impairment of LV diastolic function that can precede
systolic disorders and all types of IHD. Evaluation
of LV systolic function among patients with a histo-
ry of myocardial infarction still remains the main di-
agnostic concern during echocardiographic examina-
tion; LV diastolic function analysis often recedes into
the background. The difficulties arise from the meth-
od’s limitations, the unsettled criteria and insufficient
appreciation of diastolic function impairment as
a prognostic factor in myocardial infarction survivors.
A cohort of patients with preserved LV systolic
function after acute myocardial infarction catheter-
based coronary interventions was regarded as a spe-
cial population because no substantial segmental con-
tractility disturbances had been diagnosed in this
group. The study results demonstrate that 51 out of
83 patients presented LV diastolic dysfunction, which
in 15 cases coincided with high NT-proBNP values
that identified patients with the most evident diasto-
lic function abnormalities. It may be assumed,
although the study lacks such data, that some of these
patients demonstrated heart failure symptoms or
would develop them in the future despite their pre-
served LV systolic function and the absence of fea-
tures of traditionally defined LV remodelling.
The mechanisms that trigger diastolic abnormal-
ities in IHD are quite complex. The impairment of
active relaxation, the deterioration of myocardial com-
pliance and heterogenic LV diastole are among the
most important contributors [1]. Active myocardial
relaxation is a very hypoxia-sensitive process. Dis-
turbances of this relaxation phase are the earliest
manifestations of ischaemia in echocardiographic ex-
amination, preceding impairment of systolic function.
Chronic myocardial ischaemia and post-infarction
damage promote maladaptive processes that lead to
cardiomyocyte hypertrophy and dilatation, followed by
fibrosis and deposition of extra-cellular matrix and
ending with myocyte necrosis that significantly lim-
its LV diastolic function. IHD is usually associated
with heterogenic LV myocardial damage that causes
heterogenic inactivation and burden. During this on-
going remodelling process changes in LV electrical
activation frequently lead to asynchrony of myocar-
dial contraction, which is aggravated by heterogenic
myocardial structure, loss of myocardial contractility
and segmental hypertrophy [2]. It has been demon-
strated in many studies that LV diastolic dysfunction
is the dominant IHD abnormality and that it is present
both in patients with and without impaired LV systo-
lic function. Irrespective of systolic impairment, di-
astolic dysfunction significantly contributes to the el-
evation of LV end diastolic pressure and pulmonary
wedge pressure [3, 4]. Elevated filling pressure
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during ischaemia is commonly regarded as one of the
most important causes of effort dyspnoea in patients
with angina pectoris and those who have had a myo-
cardial infarction. Diastolic impairment is present in
95% of myocardial infarction survivors. It is always
present in the case of systolic dysfunction and mani-
fests itself in a pseudonormal or restrictive transmi-
tral inflow pattern [5]. Both in the population of inf-
arction survivors without systolic dysfunction and in
the cohort analysed by the authors relaxation abnor-
malities are dominant, probably as a result of existing
ischaemia or impaired coronary reserve.
There is increasing research to indicate that the
degree of LV diastolic impairment in the population
of patients who have experienced myocardial infarc-
tion is a powerful prognostic factor, irrespective of
LV systolic dysfunction. Diastolic disturbances of the
LV relaxation type are identified as an especially
powerful negative predictor. Among patients suffer-
ing from post-infarction heart failure there is an ev-
ident negative correlation between early mitral in-
flow deceleration time and pulmonary wedge pres-
sure. Patients with a pulmonary wedge pressure
higher than 12 mm Hg were very distinctly identi-
fied by an E-wave time shorter than 153 ms [6].
Poulsen et al. [7] reported that among post-infarc-
tion patients early inflow E-wave deceleration time
is an important and independent predictor of heart
failure symptoms. Many studies demonstrate that
early mitral inflow deceleration time is the most
powerful independent predictor of morbidity and
mortality among myocardial infarction survivors. It
has been reported that the restrictive profile of di-
astolic inflow with shortening of the early filling
phase is the most negative predictor both in cardio-
myopathy and post-infarction patients. Two signifi-
cant meta-analyses, American and Canadian, cover-
ing almost 7400 patients have recently been pub-
lished in the NEJM. These compare the clinical
course and prognosis in patients with heart failure
and in those preserved or impaired LV systolic func-
tion. Comparison was made between the two groups
in terms of clinical presentation, course of hospital-
isation, co-morbidity, re-hospitalisation and one-year
mortality and its predictors. A similar clinical course
and hospitalisation rate were observed in both
groups, the only difference being a slightly lower
mortality rate in the cohort of patients with pre-
served LV systolic function (one-year mortality 29%
vs. 32% and five-year mortality 65% vs. 68%). Dur-
ing the three five-year periods analysed the surviv-
al rate in low ejection fraction heart failure increased
(HR 0.98 per year, CI 95%, p = 0.005) with mortal-
ity in the population of patients with preserved LV
ejection fraction remaining at the same level. It
seems that a systematic increase in the incidence of
preserved LV systolic function heart failure may be
attributed to the increasing prevalence of atrial fi-
brillation, hypertension and diabetes mellitus that are
the main contributors to the development of heart
failure with preserved LV systolic function. In the
above-mentioned meta-analyses the only trend to-
ward increased survival in the heart failure popula-
tion as a whole was a statistically significant increase
in the cohort of patients with low ejection fraction.
This may be explained by the fact that there have
been several spectacular breakthroughs in the diag-
nostics and treatment of patients with low ejection
fraction, whereas heart failure with preserved LV
systolic function remains a challenging diagnostic and
therapeutic issue [8, 9]. The precise diagnostics of
diastolic dysfunction is still highly demanding and far
from perfect. Doppler echocardiography, despite its
limitations, remains the most common method of
identifying LV diastolic dysfunction [10]. These lim-
itations, as highlighted by Wita et al. [11], result from
the fact that, apart from the so-called “internal fac-
tors” determining diastole (myocardial dependent),
venous and transmitral inflow parameters reflect
a number of external factors such as preload and af-
terload of the left ventricle, left atrial systolic func-
tion, right ventricle function, characteristics of the
pericardium, valvular (especially mitral) function and
heart rhythm and rate [12, 13]. Incorporating all
these issues into the analysis of LV diastole appears
to be of vital importance. E-wave mitral inflow ve-
locity measurement in correlation with mitral ring
early diastolic speed movement in tissue Doppler
examination may contribute to a more accurate iden-
tification of isolated diastolic heart failure.
There has been an increasing number of stud-
ies in recent years suggesting the importance of
natiuretic peptides, especially BNP and NT-proBNP,
in the diagnostics of diastolic heart failure. BNP,
a very sensitive indicator of the functional condi-
tion of the heart, shows good correlation with heart
failure NYHA stage and with the haemodynamic
measurements such as pulmonary wedge pressure,
LV late diastolic pressure, ejection fraction and pul-
monary artery pressure. It is a strong predictor of
LV heart failure and mortality in the cohort of myo-
cardial infarction survivors [14–17]. The relevance
of BNP measurement in the analysis of LV diastolic
disorders was reported by Lubien et al. [18], who
observed a significant discrepancy in the average
peptide concentration between the following
groups of patients: those with relaxation disorders
— 203 pg/ml, those with pseudonormal mitral
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inflow — 294 pg/ml, those with restrictive disorders
— 402 pg/ml as against 33 pg/ml in the control group.
Subanalysis of the PRIDE trial has revealed that
among patients treated for paroxysmal dyspnoea
BNP and NT-proBNP concentration levels turned
out to be twice as high among patients with systolic
heart failure as in those with diastolic heart failure.
The same analysis also demonstrated a more accu-
rate correlation between NT-pro BNP concentration
and progression of the disease in the cohort of pa-
tients with diastolic heart failure than in patients with
systolic dysfunction [19]. The PRIDE trial results
made it possible to create the paroxysmal dyspnoea
diagnostic algorithm for emergency departments.
The work of Wita et al. [11] is a valuable contribu-
tion that supports the thesis of NT-proBNP utility
in heart diastolic function analysis. It is worth
emphasising, however, that BNP and NT-proBNP
concentration levels are influenced by a number of
factors such as left and right ventricular systolic func-
tion, valvular function, LV mass, heart rhythm, age,
sex, weight, blood pressure, renal function and res-
piratory state [20, 21]. Natiuretic peptides may prove
useful in diastolic heart failure diagnostics, provid-
ed that the results are carefully analysed in correla-
tion with clinical and echocardiographic data.
The present work indicates that, even after
modern management of myocardial infarction, the
majority of patients with preserved LV function
suffer from diastolic disorders that may evolve
into more advanced stages of heart failure. Prop-
er and accurate identification of these abnormal-
ities is of vital practical importance in tailoring
optimal diagnostics and treatment in this group
of patients.
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